[Silent myocardial ischemia. Current concepts of prognosis and therapy].
Type-I-patients with silent myocardial ischemia (SMI) have a 2-4fold higher longterm-risk for coronary-events than healthy people. With increasing gravity and duration of ischemia type-II-patients have an increased event-risk. Reliable statements about prognosis of type-III-patients are very difficult. Therapy of SMI is equivalent to therapy of "loud" ischemia and comprises: 1) treatment of cardiovascular risk-factors (nicotine, arterial hypertension, hyperlipidemia, adiposis), 2) nitrates as effective straight at the coronary stenosis, 3) beta-blockers, which influence the circadian ischemic rhythm, 4) calcium-channel-blockers with especially for nifedipine little effect, 5) thrombocyte-aggregation inhibitors and 6) invasive therapeutical methods (percutaneous transluminal coronary angioplasty [PTCA] and aorto-coronary bypass grafting [ACBG]).
Fruhwald
F M
FM
Medizinische Universitätsklinik Graz.
Eber
B
B
Rotman
B
B
Toplak
H
H
Klein
W
W
D000787:Angina Pectoris / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000401:mortality / Q000628:therapy*; D006801:Humans; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D012307:Risk Factors
Stumme Myokardischämie. Aktueller Wissensstand zur Prognose und Therapie.